Literature DB >> 31816049

History and Correlates of Smoking Cessation Behaviors Among Smokers With Serious Mental Illness.

Su Fen Lubitz1, Alex Flitter1, E Paul Wileyto2, Douglas Ziedonis3, Nathaniel Stevens1, Frank Leone4, David Mandell1, John Kimberly5, Rinad Beidas1,6,7, Robert A Schnoll1.   

Abstract

INTRODUCTION: Individuals with serious mental illness (SMI) smoke at rates two to three times greater than the general population but are less likely to receive treatment. Increasing our understanding of correlates of smoking cessation behaviors in this group can guide intervention development. AIMS AND METHODS: Baseline data from an ongoing trial involving smokers with SMI (N = 482) were used to describe smoking cessation behaviors (ie, quit attempts, quit motivation, and smoking cessation treatment) and correlates of these behaviors (ie, demographics, attitudinal and systems-related variables).
RESULTS: Forty-three percent of the sample did not report making a quit attempt in the last year, but 44% reported making one to six quit attempts; 43% and 20%, respectively, reported wanting to quit within the next 6 months or the next 30 days. Sixty-one percent used a smoking cessation medication during their quit attempt, while 13% utilized counseling. More quit attempts were associated with lower nicotine dependence and carbon monoxide and greater beliefs about the harms of smoking. Greater quit motivation was associated with lower carbon monoxide, minority race, benefits of cessation counseling, and importance of counseling within the clinic. A greater likelihood of using smoking cessation medications was associated with being female, smoking more cigarettes, and receiving smoking cessation advice. A greater likelihood of using smoking cessation counseling was associated with being male, greater academic achievement, and receiving smoking cessation advice.
CONCLUSIONS: Many smokers with SMI are engaged in efforts to quit smoking. Measures of smoking cessation behavior are associated with tobacco use indicators, beliefs about smoking, race and gender, and receiving cessation advice. IMPLICATIONS: Consideration of factors related to cessation behaviors among smokers with SMI continues to be warranted, due to their high smoking rates compared to the general population. Increasing our understanding of these predictive characteristics can help promote higher engagement in evidence-based smoking cessation treatments among this subpopulation.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved.For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2020        PMID: 31816049      PMCID: PMC7443595          DOI: 10.1093/ntr/ntz229

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  48 in total

1.  The Revised Behavior and Symptom Identification Scale (BASIS-R): reliability and validity.

Authors:  Susan V Eisen; Sharon-Lise Normand; Albert J Belanger; Avron Spiro; David Esch
Journal:  Med Care       Date:  2004-12       Impact factor: 2.983

2.  Interest in treatments to stop smoking.

Authors:  John R Hughes; Theodore W Marcy; Shelly Naud
Journal:  J Subst Abuse Treat       Date:  2008-06-11

3.  Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation.

Authors:  Benjamin Lê Cook; Geoff Ferris Wayne; E Nilay Kafali; Zimin Liu; Chang Shu; Michael Flores
Journal:  JAMA       Date:  2014-01-08       Impact factor: 56.272

4.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

5.  Trends in Use of Medications for Smoking Cessation in Medicare, 2007-2012.

Authors:  Marian Jarlenski; Seo Hyon Baik; Yuting Zhang
Journal:  Am J Prev Med       Date:  2016-03-30       Impact factor: 5.043

6.  Trends in serious quit attempts in the United States, 2009-14.

Authors:  Joe G Gitchell; Saul Shiffman; Mark A Sembower
Journal:  Addiction       Date:  2017-01-26       Impact factor: 6.526

7.  Softening Among U.S. Smokers With Psychological Distress: More Quit Attempts and Lower Consumption as Smoking Drops.

Authors:  Margarete C Kulik; Stanton A Glantz
Journal:  Am J Prev Med       Date:  2017-10-10       Impact factor: 5.043

8.  Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report.

Authors:  Douglas Ziedonis; Brian Hitsman; Jean C Beckham; Michael Zvolensky; Lawrence E Adler; Janet Audrain-McGovern; Naomi Breslau; Richard A Brown; Tony P George; Jill Williams; Patrick S Calhoun; William T Riley
Journal:  Nicotine Tob Res       Date:  2008-12       Impact factor: 4.244

9.  Cognitive and Behavioral Predictors of Quit Attempts and Biochemically-Validated Abstinence During Pregnancy.

Authors:  Joanne L Emery; Stephen Sutton; Felix Naughton
Journal:  Nicotine Tob Res       Date:  2017-05-01       Impact factor: 4.244

10.  Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.

Authors:  Robert M Anthenelli; Neal L Benowitz; Robert West; Lisa St Aubin; Thomas McRae; David Lawrence; John Ascher; Cristina Russ; Alok Krishen; A Eden Evins
Journal:  Lancet       Date:  2016-04-22       Impact factor: 79.321

View more
  2 in total

1.  If at First You Don't Try ….

Authors:  Matthew J Carpenter; John R Hughes
Journal:  Nicotine Tob Res       Date:  2020-08-24       Impact factor: 4.244

2.  History and Correlates of Smoking Cessation Behaviors Among Individuals With Current or Past Major Depressive Disorder Enrolled in a Smoking Cessation Trial.

Authors:  Mackenzie Hosie Quinn; Matthew Olonoff; Anna-Marika Bauer; Erica Fox; Nancy Jao; Su Fen Lubitz; Frank Leone; Jacqueline K Gollan; Robert Schnoll; Brian Hitsman
Journal:  Nicotine Tob Res       Date:  2022-01-01       Impact factor: 5.825

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.